Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14)

Market Cap	5.20B +37.2%
Revenue (ttm)	904.27M -32.7%
Net Income	391.88M -4.4%
EPS	0.51 -4.2%
Shares Out	n/a
PE Ratio	13.27
Forward PE	n/a
Dividend	0.67 (20.88%)
Ex-Dividend Date	Jan 30, 2026

Volume	244,500
Average Volume	173,180
Open	3.190
Previous Close	3.170
Day's Range	3.150 - 3.290
52-Week Range	2.110 - 3.750
Beta	n/a
RSI	49.48
Earnings Date	Mar 31, 2026

About SGX:T14

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, tumor, chronic, and other diseases, as well as tonic drugs. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Li...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1915
• Employees: 4,619
• Stock Exchange: Singapore Exchange
• Ticker Symbol: T14

Financial Performance

In 2025, SGX:T14's revenue was 4.92 billion, a decrease of -32.70% compared to the previous year's 7.31 billion. Earnings were 2.13 billion, a decrease of -4.41%.

Financial numbers in CNY